Previous Close | 15.85 |
Open | 15.95 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 15.65 - 16.40 |
52 Week Range | 14.40 - 30.35 |
Volume | 478,157 |
Avg. Volume | 711,285 |
Market Cap | 603.605M |
Beta | 1.85 |
PE Ratio (TTM) | 12.45 |
EPS (TTM) | 1.28 |
Earnings Date | Apr 30, 2018 - May 4, 2018 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24.86 |
--Company Re-aligns Management Responsibilities-- PHILADELPHIA , April 20, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Maureen M. Cavanaugh to the newly created ...
Zacks Value Investor Highlights: Lannett, Emerge Energy, Roadrunner, GameStop and Micron
Lannett Company Inc’s (NYSE:LCI) most recent return on equity was a substandard 8.09% relative to its industry performance of 10.88% over the past year. Though LCI’s recent performance is underwhelming,Read More...
Lannett Company Inc at Raymond James Institutional Investors Conference
PHILADELPHIA, March 23, 2018 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced the appointments of Grant Brock as vice president operations and Alicia Evolga as vice president of marketing. Grant joined the company last month and Alicia begins April 2, 2018.
Is Lannett Company (LCI) a great pick from the value investor's perspective right now? Read on to know more.
Lannett Co. Inc. said Monday, in a move to create new revenues streams, it has entered into separate agreements with three strategic alliance partners. Initially, the agreements cover one product from each partner: Diclofenac ER, a nonsteroidal anti-inflammatory drug used to treat to treat mild to moderate pain or signs and symptoms of osteoarthritis or rheumatoid arthritis, and Fluvastatin ER, a cholesterol-lowering medication. Crew said Lannett expects to launch Diclofenac ER within the next few months.
PHILADELPHIA, March 12, 2018 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that it has entered into separate agreements with three strategic alliance partners. Under two of the agreements, Lannett will serve as the exclusive U.S. distributor for certain off-patent products manufactured by the partners. Initially, the agreements cover one product from each partner, Diclofenac ER and Fluvastatin ER. Under the third agreement, Lannett will provide five of its currently marketed products to Pharmaceutical Associates, Inc. (PAI) for repackaging into unit dose cups and distribution into the managed care and hospital markets. For all the above transactions, Lannett will receive a percentage of the net profits. Other financial terms were not disclosed. For the 12 months ended January 2018, total U.S. generic sales of Diclofenac ER were approximately $8.7 million, and total U.S. sales of Fluvastatin ER were approximately $15.5 million, according to IMS. Currently, Diclofenac ER has one generic competitor and Fluvastatin ER has three. Diclofenac ER is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild-to-moderate pain and helps to relieve symptoms of arthritis and Fluvastatin ER is a cholesterol-lowering drug.
Stock Monitor: Pacira Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 9, 2018 / Active-Investors.com has just released a free earnings report on Lannett Co., Inc. (NYSE: LCI ). If you want ...
PHILADELPHIA , Feb. 27, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at three investor conferences in March. The schedule and details are as follows: ...
Q2 2018 Lannett Company Inc Earnings Call
NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Workday, ...
Shares tumbled after the generic-drug maker shared quarterly results that came up short of expectations.
On a per-share basis, the Philadelphia-based company said it had net income of 37 cents. Earnings, adjusted for non-recurring costs and amortization costs, were $1.06 per share. The results exceeded Wall ...
--Adjusted EPS Higher Than Expected; Full-Year Adjusted Profitability Expected to Improve-- PHILADELPHIA , Feb. 7, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results ...
PHILADELPHIA , Feb. 7, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the company voluntarily made a $25 million payment against its Term Loans. "Paying down our debt ...
Under the agreement, Bedrosian will work with the company on several important projects primarily involving existing and new partnering efforts to expand and diversify opportunities, including but not limited to spearheading the effort to transition and strengthen the company's existing contractual relationships with its key partners. Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.
PHILADELPHIA , Jan. 31, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2018 second quarter on Wednesday, February 7, 2018 , ...
Lannett Company Inc (NYSE:LCI), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NYSE in the over the last fewRead More...
PHILADELPHIA , Jan. 18, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that Timothy C. Crew , the company's recently appointed chief executive officer (CEO), has been added to the ...
Lannett shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Haeggquist & Eck, LLP, a leading shareholder rights litigation firm, is investigating whether certain directors and officers of Lannett Company, Inc. breached their fiduciary duties to the Company and its shareholders.
A Relative Strength Rating upgrade for Lannett shows improving technical performance. Will it continue?
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Lannett Co., Inc. Here are 5 ETFs with the largest exposure to LCI-US. Comparing the performance and risk of Lannett Co., Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)